Form 4: Alkermes Director Alva Reports Stock Option and Restricted Stock Unit Awards

Emily Peterson Alva, a director of Alkermes plc, reports the acquisition of stock options and restricted stock units.

Summary

• On June 4, 2024, Emily Peterson Alva, a director of Alkermes plc, filed a Form 4 with the SEC.
• The filing reports the acquisition of 8,013 restricted stock units and 17,492 non-qualified stock options on May 31, 2024.
• These awards vest on May 31, 2025, and the stock options expire on May 31, 2034.
• The filing also details adjustments to previously granted equity awards related to the separation of Alkermes' oncology business into Mural Oncology plc on November 17, 2023.
• The adjustments were made to preserve the value of the original awards.
• Alva also has a power of attorney on file, granting certain individuals the authority to act on her behalf in matters related to SEC filings.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment as it primarily reports transactions. The acquisition of equity could be seen as a slightly positive signal.

Positives

• The acquisition of stock options and restricted stock units could indicate confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the equity awards suggest a multi-year commitment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The adjustments to equity awards due to the Mural Oncology separation are specific to Alkermes' corporate restructuring.

Comparison to Industry Standards

• Equity compensation is a standard practice in the pharmaceutical industry to align the interests of directors and shareholders.
• Companies like Biogen, Vertex, and Gilead also use stock options and restricted stock units as part of their compensation packages for directors and executives.
• The vesting schedules and exercise prices are generally in line with industry norms for similar roles and company size.

Stakeholder Impact

• Shareholders are informed about the equity holdings of a director.
• Employees may be indirectly affected by the company's overall performance, which is influenced by the alignment of director interests with shareholder value.

Key Dates